Literature DB >> 18829485

Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.

Nima Sharifi1, Elaine M Hurt, Suneetha B Thomas, William L Farrar.   

Abstract

PURPOSE: Advanced prostate cancer is first treated with androgen deprivation therapy. However, tumors become resistant to and grow despite castrate levels of testosterone. Growth and proliferation of CRPC is mediated by gain-of-function changes in the AR and AR reactivation. Expression of manganese superoxide dismutase (SOD2), which regulates cellular ROS, is markedly down-regulated in CRPC when compared with hormone-responsive tumors. EXPERIMENTAL
DESIGN: Here, we knocked down SOD2 expression in AR-expressing LNCaP prostate cancer cells and determined gene expression changes, transcription factor binding, and AR transcription activity in SOD2 knockdown cells.
RESULTS: SOD2 knockdown results in an increase in ROS. Gene expression changes induced by SOD2 knockdown results in the up-regulation of genes that are also androgen responsive and 46% of genes up-regulated 2-fold by the androgen ligand R1881 are also up-regulated to the same extent with SOD2 knockdown. The induction of many of these genes with SOD2 knockdown, such as VEGFA and FKBP5, is reversible with the antioxidant N-acetylcysteine, suggesting that this mechanism is directly linked to ROS. Furthermore, an array for transcription factor DNA-binding activity shows that SOD2 knockdown induces DNA binding by several transcription factors, including AR. SOD2 knockdown-induced AR activation was confirmed by electrophoretic mobility shift assay and luciferase activity, and both were readily reversible with N-acetylcysteine.
CONCLUSIONS: These findings show that down-regulation of SOD2 induces AR activity in a ROS-dependent manner, and suggest that there may be a role for antioxidant therapy in CRPC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829485      PMCID: PMC2670581          DOI: 10.1158/1078-0432.CCR-08-0591

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression.

Authors:  Bruno Perillo; Maria Neve Ombra; Alessandra Bertoni; Concetta Cuozzo; Silvana Sacchetti; Annarita Sasso; Lorenzo Chiariotti; Antonio Malorni; Ciro Abbondanza; Enrico V Avvedimento
Journal:  Science       Date:  2008-01-11       Impact factor: 47.728

3.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.

Authors:  S F Shariat; B Andrews; M W Kattan; J Kim; T M Wheeler; K M Slawin
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

4.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.

Authors:  T Chen; L H Wang; W L Farrar
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

5.  Androgen-induced cell growth and c-myc expression in human non-transformed epithelial prostatic cells in primary culture.

Authors:  I S Silva; D M Morsch; L Urnauer; P M Spritzer
Journal:  Endocr Res       Date:  2001 Feb-May       Impact factor: 1.720

6.  A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer.

Authors:  C M Perez-Stable; A Pozas; B A Roos
Journal:  Mol Cell Endocrinol       Date:  2000-09-25       Impact factor: 4.102

7.  Stable suppression of tumorigenicity by virus-mediated RNA interference.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

8.  Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.

Authors:  Soo Ok Lee; Wei Lou; Min Hou; Fernando de Miguel; Lizabeth Gerber; Allen C Gao
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

Review 9.  Molecular biology of the androgen receptor.

Authors:  Edward P Gelmann
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

10.  Transcriptional programs activated by exposure of human prostate cancer cells to androgen.

Authors:  Samuel E DePrimo; Maximilian Diehn; Joel B Nelson; Robert E Reiter; John Matese; Mike Fero; Robert Tibshirani; Patrick O Brown; James D Brooks
Journal:  Genome Biol       Date:  2002-06-14       Impact factor: 13.583

View more
  16 in total

1.  Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells.

Authors:  Farideh Mehraein-Ghomi; Hirak S Basu; Dawn R Church; F Michael Hoffmann; George Wilding
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

2.  Survivin is not induced by novel taxanes.

Authors:  Nima Sharifi; Jun Qi; Susan Bane; Shubhada Sharma; Rui Li; Robert Robey; William D Figg; William L Farrar; David G I Kingston
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

3.  Efficacy of androgen deprivation therapy and the role of oxidative stress.

Authors:  D K Price
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

4.  Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress.

Authors:  Joo Hyoung Lee; Minsung Kang; Hong Wang; Gurudatta Naik; James A Mobley; Guru Sonpavde; W Timothy Garvey; Victor M Darley-Usmar; Selvarangan Ponnazhagan
Journal:  FASEB J       Date:  2017-01-09       Impact factor: 5.191

5.  Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Authors:  Elena V Fernandez; Kelie M Reece; Ariel M Ley; Sarah M Troutman; Tristan M Sissung; Douglas K Price; Cindy H Chau; William D Figg
Journal:  Mol Pharmacol       Date:  2015-03-31       Impact factor: 4.436

6.  A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Wanling Xie; Sarah Drouin; Mari Nakabayashi; Mark Pomerantz; Gwo-Shu Mary Lee; Philip W Kantoff; Nima Sharifi
Journal:  Prostate       Date:  2016-06-21       Impact factor: 4.104

Review 7.  Iron and Neurodegeneration: Is Ferritinophagy the Link?

Authors:  Giorgio Biasiotto; Diego Di Lorenzo; Silvana Archetti; Isabella Zanella
Journal:  Mol Neurobiol       Date:  2015-10-14       Impact factor: 5.590

8.  Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.

Authors:  Kathleen C Light; Neeraj Agarwal; Eli Iacob; Andrea T White; Anita Y Kinney; Timothy A VanHaitsma; Hannah Aizad; Ronald W Hughen; Lucinda Bateman; Alan R Light
Journal:  Psychoneuroendocrinology       Date:  2013-09-06       Impact factor: 4.905

9.  Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance.

Authors:  Naseruddin Höti; Punit Shah; Yingwei Hu; Shuang Yang; Hui Zhang
Journal:  Proteomics       Date:  2017-03       Impact factor: 3.984

Review 10.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.